HRP20190878T1 - Modificirane aminokiseline koje sadrže azidnu grupu - Google Patents

Modificirane aminokiseline koje sadrže azidnu grupu Download PDF

Info

Publication number
HRP20190878T1
HRP20190878T1 HRP20190878TT HRP20190878T HRP20190878T1 HR P20190878 T1 HRP20190878 T1 HR P20190878T1 HR P20190878T T HRP20190878T T HR P20190878TT HR P20190878 T HRP20190878 T HR P20190878T HR P20190878 T1 HRP20190878 T1 HR P20190878T1
Authority
HR
Croatia
Prior art keywords
conjugate
polypeptide
compound
amino acid
segment
Prior art date
Application number
HRP20190878TT
Other languages
English (en)
Croatian (hr)
Inventor
Ryan STAFFORD
Christopher D. Thanos
Wenjin Yang
Original Assignee
Sutro Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma, Inc. filed Critical Sutro Biopharma, Inc.
Publication of HRP20190878T1 publication Critical patent/HRP20190878T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20190878TT 2012-08-31 2013-08-30 Modificirane aminokiseline koje sadrže azidnu grupu HRP20190878T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696087P 2012-08-31 2012-08-31
PCT/US2013/057677 WO2014036492A1 (en) 2012-08-31 2013-08-30 Modified amino acids comprising an azido group
EP13762659.4A EP2890402B1 (en) 2012-08-31 2013-08-30 Modified amino acids comprising an azido group

Publications (1)

Publication Number Publication Date
HRP20190878T1 true HRP20190878T1 (hr) 2019-07-26

Family

ID=49170897

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190878TT HRP20190878T1 (hr) 2012-08-31 2013-08-30 Modificirane aminokiseline koje sadrže azidnu grupu
HRP20220455TT HRP20220455T1 (hr) 2012-08-31 2013-08-30 Modificirane aminokiseline koje sadrže azid grupu

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20220455TT HRP20220455T1 (hr) 2012-08-31 2013-08-30 Modificirane aminokiseline koje sadrže azid grupu

Country Status (17)

Country Link
US (7) US9682934B2 (https=)
EP (3) EP2890402B1 (https=)
JP (2) JP6826367B2 (https=)
KR (1) KR102182800B1 (https=)
CN (1) CN104981254B (https=)
AU (2) AU2013308494B2 (https=)
BR (1) BR112015004022B1 (https=)
CA (1) CA2881978C (https=)
DK (2) DK3584255T3 (https=)
ES (2) ES2728864T3 (https=)
HR (2) HRP20190878T1 (https=)
HU (1) HUE045227T2 (https=)
IL (1) IL237401B (https=)
PL (2) PL2890402T3 (https=)
SG (1) SG11201501464TA (https=)
SI (2) SI2890402T1 (https=)
WO (1) WO2014036492A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873793C (en) 2012-05-18 2022-02-22 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2898085B1 (en) 2012-09-24 2019-01-23 MedImmune Limited Cell lines
AU2014229999B2 (en) 2013-03-15 2019-09-12 Medimmune Limited Novel nucleic acid molecules
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
WO2015006555A2 (en) * 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EP3030545B1 (en) 2013-08-05 2020-10-07 MedImmune Limited Amino acid derivatives
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
TWI614264B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 含胜肽核的多臂接合物及其應用
TWI617319B (zh) * 2015-09-01 2018-03-11 免疫功坊股份有限公司 用以治療病理性血栓的融合蛋白
CN108367021A (zh) * 2015-10-15 2018-08-03 希望之城 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
WO2017132615A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス，インク． 非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
SG11202006101WA (en) 2017-12-29 2020-07-29 Scripps Research Inst Unnatural base pair compositions and methods of use
CN112004547A (zh) 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
JPWO2019240288A1 (ja) * 2018-06-14 2021-07-26 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
DK3817775T3 (da) 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
GB201817444D0 (en) 2018-10-26 2018-12-12 Res & Innovation Uk Methods and compositions
SG11202102930YA (en) 2018-11-08 2021-04-29 Synthorx Inc Interleukin 10 conjugates and uses thereof
CN109456284A (zh) * 2018-11-13 2019-03-12 南方医科大学 一种含取代联苯的查尔酮及其应用
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
AU2020291535A1 (en) 2019-06-14 2022-01-20 The Scripps Research Institute Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
CN110551195B (zh) * 2019-08-01 2022-08-09 天津科技大学 一种α-突触核蛋白聚集诱导发光体系及其构建与应用
EP4017540A1 (en) 2019-08-23 2022-06-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
CN111217721A (zh) * 2020-01-20 2020-06-02 赛纳生物科技(北京)有限公司 一种含有叠氮基团的水凝胶单体的制备方法
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
PE20231648A1 (es) 2020-04-22 2023-10-17 Merck Sharp And Dohme Llc CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
US12351850B2 (en) 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
KR20230052958A (ko) 2020-08-19 2023-04-20 박사이트, 인코포레이티드 운반-단백질 폴리삭카라이드 접합 방법
US11510994B2 (en) * 2021-01-29 2022-11-29 EqIP, LLC Linkers for improving the stability of bioconjugates and the selectivity of payload release
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281480A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
EP4689127A1 (en) 2023-04-03 2026-02-11 Sutro Biopharma, Inc. Rf1 ko e. coli strains
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
CN117658866B (zh) * 2023-12-07 2026-02-03 苏州爱玛特生物科技有限公司 一种叠氮氨基酸衍生物的合成方法
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025179135A1 (en) * 2024-02-23 2025-08-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using targeted pore-forming agents
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
PL451305A1 (pl) * 2025-02-25 2025-09-01 Politechnika Warszawska Pochodna kwasu 3-ureidopropanowego i sposób jej otrzymywania

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10507643A (ja) 1994-10-21 1998-07-28 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2280930C (en) 1997-02-12 2010-04-06 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP4011124B2 (ja) 1997-06-06 2007-11-21 協和醗酵工業株式会社 化学修飾ポリペプチド
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
CA2320156A1 (en) 1997-09-26 1999-04-08 Uab Research Foundation Reduced antigenic cells and uses therefor
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE19748489A1 (de) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1107998B1 (en) 1998-08-28 2004-02-04 Gryphon Sciences Method for the preparation of polyamide chains of precise length, their conjugates with proteins
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP4805432B2 (ja) 1998-12-28 2011-11-02 ランクセス・ドイチュランド・ゲーエムベーハー 木質材又は木質複合材を製造する際に使用される接着剤混入用薬剤
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6384105B1 (en) 1999-04-16 2002-05-07 William Marsh Rice University Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
MXPA02006215A (es) 1999-12-22 2003-10-15 Nektar Therapeutics Al Corp Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol).
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
ATE419354T1 (de) 2000-02-25 2009-01-15 Us Gov Health & Human Serv Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
BR0110927A (pt) 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
AU2002346373A1 (en) 2001-11-09 2003-05-19 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP5259046B2 (ja) 2002-08-19 2013-08-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 改良されたインビトロ・タンパク質合成の方法
EP2410331B1 (en) 2003-06-18 2015-09-23 The Scripps Research Institute Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
PT1740616E (pt) 2004-04-30 2012-03-23 Inst Nat Sante Rech Med Anticorpo anti-rtf
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
CN101048506B (zh) 2004-10-27 2013-06-26 斯克利普斯研究院 体内掺入非天然氨基酸的正交翻译组分
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007215566A1 (en) 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
WO2008066583A2 (en) 2006-06-29 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
JP2010502221A (ja) 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み
US20100098630A1 (en) 2006-12-28 2010-04-22 Ambrx, Inc. Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2010051056A2 (en) 2008-03-11 2010-05-06 Ambrx, Inc. ANTI-FcεRI POLYPEPTIDES AND THEIR USES
CA2726050A1 (en) * 2008-05-30 2009-12-10 Siemens Medical Solutions Usa, Inc. Achievement of high therapeutic index through molecular imaging guided targeted drug treatment
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
GB2470770A (en) 2009-06-04 2010-12-08 Medical Res Council Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
WO2011044255A1 (en) * 2009-10-06 2011-04-14 The Ohio State University Pyrrolysine analogs
EP2640745B1 (en) 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
EP2859017B1 (en) * 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group

Also Published As

Publication number Publication date
EP2890402B1 (en) 2019-04-17
SG11201501464TA (en) 2015-03-30
KR20150048781A (ko) 2015-05-07
US20170267637A1 (en) 2017-09-21
AU2018203568B2 (en) 2020-08-13
DK3584255T3 (da) 2022-04-04
US9994527B2 (en) 2018-06-12
JP2015529208A (ja) 2015-10-05
US20140066598A1 (en) 2014-03-06
EP3584255B1 (en) 2022-02-16
US20170260137A1 (en) 2017-09-14
HK1210034A1 (en) 2016-04-15
US20200361870A1 (en) 2020-11-19
CA2881978A1 (en) 2014-03-06
SI3584255T1 (sl) 2022-05-31
ES2907763T3 (es) 2022-04-26
DK2890402T3 (da) 2019-07-15
EP3584255A1 (en) 2019-12-25
IL237401A0 (en) 2015-04-30
US10730837B2 (en) 2020-08-04
ES2728864T3 (es) 2019-10-29
CN104981254A (zh) 2015-10-14
SI2890402T1 (sl) 2019-07-31
US9682934B2 (en) 2017-06-20
US20230139442A1 (en) 2023-05-04
BR112015004022A2 (pt) 2019-09-03
US10112900B2 (en) 2018-10-30
EP2890402A1 (en) 2015-07-08
KR102182800B1 (ko) 2020-11-25
HUE045227T2 (hu) 2019-12-30
US20250236594A1 (en) 2025-07-24
JP6826367B2 (ja) 2021-02-03
PL3584255T3 (pl) 2022-05-16
WO2014036492A1 (en) 2014-03-06
CA2881978C (en) 2023-03-14
HRP20220455T1 (hr) 2022-05-27
PL2890402T3 (pl) 2019-08-30
JP2019167340A (ja) 2019-10-03
EP4074728A1 (en) 2022-10-19
BR112015004022B1 (pt) 2023-04-25
US20190047958A1 (en) 2019-02-14
US11548852B2 (en) 2023-01-10
AU2013308494A1 (en) 2015-03-26
IL237401B (en) 2018-12-31
AU2018203568A1 (en) 2018-06-14
AU2013308494B2 (en) 2018-03-01
US12269801B2 (en) 2025-04-08
AU2018203568A2 (en) 2018-10-18
CN104981254B (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
HRP20190878T1 (hr) Modificirane aminokiseline koje sadrže azidnu grupu
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
JP2015529208A5 (https=)
ES2683372T3 (es) Derivados de GLP-1 acilados con un conector nuevo
SG10201810743WA (en) Conjugation methods
JP2011057686A5 (https=)
PE20120582A1 (es) Conjugados de insulina cristalina
WO2012166653A3 (en) Methods for coupling targeting peptides onto recombinant lysosomal enzymes
EP2582719A4 (en) Single chain insulin agonists exhibiting high activity at the insulin receptor
BR112013031028A2 (pt) conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
EA201991268A2 (ru) Получение конъюгатов "майтансиноид-антитело" одностадийным способом
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
IN2014DN03424A (https=)
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
EA201391400A1 (ru) Способ производства конъюгатов с улучшенной гомогенностью
BR112014029972A2 (pt) reagentes de conjugação
WO2009044918A1 (ja) ニューロメジンｕ誘導体
WO2022235972A8 (en) Lipid compositions comprising peptide-lipid conjugates
MX2011011876A (es) Composiciones de profarmaco de alta penetracion de peptidos y compuestos relacionados con peptidos.
JP2013540771A5 (https=)
EP3747891A3 (en) Compositions and methods for conjugating oligonucleotides
WO2011071280A3 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
HK1203364A1 (en) Use of n-hydroxysuccinimide to improve conjugate stability
MX2013010392A (es) Proteinas de fusion npp1.
HRP20200905T1 (hr) Au multikomponentni nanomaterijali i sintezne metode